Fundraising FoxAcumen Pharmaceuticals (NASDAQ: ABOS)
2 known investors
Find your way into Acumen Pharmaceuticals (NASDAQ: ABOS)
Sign up to see every warm intro you have to Acumen Pharmaceuticals (NASDAQ: ABOS)
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Acumen Pharmaceuticals (NASDAQ: ABOS) team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.
Founders & leadership
JD
Jim Doherty, PhD
ES
Eric Siemers, MDDr. Eric Siemers, an MD with over two decades of experience in neurodegenerative disease research across academia and industry, is Chief Medical Officer of Acumen Pharmaceuticals, where he specializes in clinical trial design and biomarkers for conditions including Alzheimer's, Parkinson's, and Huntington's disease.
MZ
Matthew Zuga
RB
Russell Barton, MS
AS
Amy Schacterle, PhD
DM
Derek MeisnerDerek Meisner is a corporate executive with background in legal, operational, and compliance matters. He previously served as a partner at an international law firm and as Branch Chief at the U.S. Securities and Exchange Commission.
JB
Julie BockenstetteJulie Bockenstette began her pharmaceutical career as a sales representative before transitioning to human resources, where she has held roles spanning employee relations, compensation, talent management, and global HR transformation initiatives at organizations with thousands of employees.
LS
Liean Schenck, MS
Investors · 2
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $222.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $176.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $183.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $145.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Acumen Pharmaceuticals (NASDAQ: ABOS) do?
- Acumen Pharmaceuticals is developing treatments for Alzheimer's disease and other neurodegenerative diseases, focusing on understanding and targeting amyloid beta oligomers in neurodegeneration.
- Who are Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors?
- Acumen Pharmaceuticals (NASDAQ: ABOS)'s investors include K2 HealthVentures, Western Technology Investment.